The role of the podocyte in glomerulosclerosis

Current Opinion in Nephrology and Hypertension

Volumn 8, Issue 4, 1999, Pages 489-497

  Kriz, Wilhelm ^a,c   Lemley, Kevin V ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CAPILLARY BASEMENT MEMBRANE; CELL LOSS; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; HUMAN; NONHUMAN; PODOCYTE; PRIORITY JOURNAL;

ANIMALS; EPITHELIUM; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY GLOMERULUS;

EID: 0033452520     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199907000-00014     Document Type: Article

References (117)

1. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54:687-697. A general explanation of the mechanism (and review of the supporting studies) for the podocyte model of 'classic' FSGS.
2. Drumond MC, Deen WM. Structural determinants of glomerular hydraulic permeability. Am J Physiol 1994; 266:F1-F12.
3. Edwards A, Dean WM, Daniels BS. Hindorod transport of macromolecules in isolated glomeruli. I. Diffusion across intact and cell free capillaries. Biophys J 1997; 72:204-213.
4. Drumond MC, Kristal B, Myers BD, Deen WM. Structural basis for reduced glomerular filtration capacity in nephrotic humans. J Clin Invest 1994; 94:1187-1195.
5. Laurens WEAA, Battaglia C, Foglieni C, de Vos R, Malanchini B, van Damme BJC et al. Direct podocyte damage in the single nephron leads to albuminuria in vivo. Kidney Int 1995; 47:1078-1086.
6. Bolton GR, Deen WM, Daniels BS. Assessment of the charge selectivity of glomerular basement membrane using Ficoll sulfate. Am J Physiol 1998; 274:F889-F896.
7. Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropthies. Kidney Int 1997; 63 (Suppl.):S54-S57.
8. Squarer A, Lemley KV, Ambalavanan S, Kristal B, Deen WM, Sibley R et al. Mechanisms of progressive glomerular injury in membranous nephropathy. J Am Soc Nephrol 1998; 9:1389-1398.
9. Kriz W, Elger M, Mundel P, Lemley KV. Structure-stabilizing forces in the glomerular tuft. J Am Soc Nephrol 1995; 5:1731-1739.
10. Kriz W, Kretzler M, Nagata M, Provoost AP, Shirato I, Uiker S et al. A frequent pathway to glomerulosclerosis: deterioration of tuft architecturepodocyte damage-segmental sclerosis. Kidney Blood Press Res 1996; 19:245-253.
11. Kriz W, Hosser H, Hähnel B, Simons JL, Provoost AP. Development of vascular pole associated glomerulosclerosis in the fawn-hooded rat. J Am Soc Nephrol 1998; 9:381-396.
12. Daniels BS, Hostetter TH. Adverse effects of growth in the glomerular microcirculation. Am J Physiol 1990; 258:F1409-F1416.
13. Matsumae T, Fukuzaki M, Takahashi S, Naito S. Two different pathways of glomerular enlargement in adults with focal and segmental glomerulosclerosis: a morphometric study. Am J Nephrol 1998; 18:21-27.
14. Mundel P, Reiser J, Zuniga Boree A, Davidson G, Pavenstädt H, Kriz W, et al. Rearrangements of cytoskeleton and cell contacts induce process formation and postmitotic differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236:248-258. This study describes a new podocyte cell culture model that yields large amounts of quite differentiated cells. Allows studies on podocyte process formation in vitro.
15. Kobayashi N, Reiser J, Kuriyama R, Kriz W, Mundel P. Nonuniform microtubular polarity, established by CHO1/MKLP1 motor protein is necessary for process formation of podocytes. J Cell Biol 1998; 143:1961-1970.
16. Reiser J, Kriz W, Mundel P. The glomerular slit diaphragm (GSD) is a modified adherens junction (AJ) [abstract]. J Am Soc Nephrol 1998; 9:507A.
17. Mundel P, Heid HW, Mundel TM, Krüger M, Reiser J, Kriz W. Synaptopodin, an actin-associated protein in telencephalic dendrites and renal podocytes. J Cell Biol 1997; 139:193-204. Synaptopodin defines a new family of actin-associated proteins. The differentiation of podocytes into an arborized phenotype is associated with the expression of this protein.
18. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephroris. Am J Pathol 1997; 151:1141-1152.
19. Matsui K, Breiteneder-Geleff S, Kerjaschki D. Epitope-specific antibodies in the 43-kD glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes. J Am Soc Nephrol 1998; 9:2013-2026. Together with reference 16, a 43 000 Mr transmembrane protein (podoplanin) is described, the expression of which is strongly downregulated during PAN nephrosis and is proposed to be associated with the maintenance of the normal interdigitating pattern of foot processes and its loss (effacement).
20. Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H, et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell 1998; 1:575-582.
21. Lenkkeri U, Antignac C, Kashtan CE, Holmberg C, Olsen A, Kestila M, et al. Structure of the gene for congenital nephrotic syndrome of the Finnish type (NPHS1) and characterization of mutations. Am J Hum Genet 1999; 64:51-61. Together with reference 20, the characterization of a new glomerular protein, nephrin, is described. Numerous novel mutations (many missense mutations) were found in the gene for nephrin, the product of NPHS1. Mutations were also found in the NPHS1 promoter region.
22. Hugo C, Nangaku M, Shankland SJ, Pichler R, Gordon K, Amieva MR, et al. The plasma membrane-actin linking protein, ezrin, is a glomerular epithelial cell marker in glomerulogenesis, in the adult kidney and in glomerular injury. Kidney Int 1998; 54:1934-1944. The title says it all!
23. Wiggins RC, Wiggins JE, Goyal M, Wharram BL, Thomas PE. Molecular cloning of cDNAs encoding human GLEPP1, a membrane protein tyrosine phosphatase; characterization of the GLEPP1 protein distribution in human kidney and assignment of the GLEPP1 gene to human chromosome 12p12p13. Genomics 1995; 27:174-181.
24. Yamamoto T, Feng L, Mizuno T, Hirose S, Kawasaki K, Yaoita E, et al. Expression of mRNA for natriuretic peptide receptor subtypes in bovine kidney. Am J Physiol 1994; 267;F318-F324.
25. Zhao J, Ardaillou N, Lu CY, Placier S, Pham P, Badre L, et al. Characterization of C-type natriuretic peptide receptors in human mesangial cells. Kidney Int 1994; 46:717-725.
26. Mundel P, Gambaryan S, Bachmann S, Koesling D, Kriz W. Immunolocalization of soluble guanylyl cyclase subunits in rat kidney. Histochemistry 1995; 103:75-79.
27. Pavenstädt H, Spath M, Fiedler C, Fischer R, Schlunck G, Wanner C et al. Effect of bradykinin on the cytosolic free calcium activity and phosphoinositol turnover in human glomerular epithelial cells. Renal Physiol Biochem 1992; 15:277-288.
28. Ardaillou N, Blaise V, Costenbader K, Vassitch Y, Ardaillou R. Characterization of a B2-bradykinin receptor in human glomerular podocytes. Am J Physiol 1996; 271:F754-F761.
29. Gloy J, Henger A, Fischer KG, Nitschke R, Mundel P, Bleich M, et al. Angiotensin II depolarizes podocytes in the intact glomerulus of the rat. J Clin Invest 1997; 99:2772-2781. Together with reference 30, the effect of angiotensin II on podocytes is documented.
30. Henger A, Huber T, Fischer KG, Nitschke R, Mundel P, Schollmeyer P, et al. Angiotensin II increases the cytostolic calcium activity in rat podocytes in culture. Kidney Int 1997; 52:687-693.
31. Massfelder T, Stewart AF, Endlich K, Soifer N, Judes C, Helwig JJ. Parathyroid hormone-related protein detection and interaction with NO and cyclic AMP in the renovascular system. Kidney Int 1996; 50:1591-1603.
32. Yamamoto T, Watanabe T, Ikegaya N, Fujigaki Y, Matsui K, Masaoka H, et al. Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis. J Am Soc Nephrol 1998; 9:2253-2261.
33. Ford MD, Cauchi J, Greferath U, Bertram JF. Expression of fibroblast growth factors and their receptors in rat glomeruli. Kidney Int 1997; 51:1729-1738.
34. Fries JW, Sandstrom DJ, Meyer TW, Rennke HG. Glomerular hypertrophy and epithelial cell injury modulate progressive glomerulosclerosis in the rat. Lab Invest 1989; 60:205-218.
35. Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int 1992; 42:148-160.
36. Kriz W, Hähnel B, Rösener S, Elger M. Long-term treatment of rats with FGF-2 results in focal segmental glomeruloscleroris. Kidney Int 1995; 48:1435-1450.
37. Tenschert S, Elger M, Lemley KV. Glomerular hypertrophy after subtotal nephrectomy: relationship to early glomerular injury. Virchows Arch 1995; 426:509-517.
38. Wang Y, Bass PS, Evans B, Davies DR. Glomerular epithelial cell endocytosis in puromycin-induced glomerulopathy. Nephron 1992; 62:84-89.
39. Nagata M, Yamaguchi Y, Komatsu Y, Ito K. Mitosis and the presence of binucleate cells among glomerular podocytes in diseased human kidneys. Nephron 1995; 70:68-71.
40. Lo A, Brown HG, Fivush BA, Neu AM, Racusen LC. Renal disease in Down syndrome: autopsy study with emphasis on glomerular lesions. Am J Kidney Dis 1998; 31:329-335.
41. Shankland SJ. The growing role for the cyclin kinase inhibitor p27Kip1 in renal disease. Kidney Int 1998; 54:2241-2242. A review of the role of this CKI in renal disease.
42. Wolf G, Neilson EG. Morphogenic cues that modulate podocyte growth. Kidney Int 1998; 53:1087-1088.
43. Shankland SJ. Cell-cycle control and renal disease. Kidney Int 1997; 52:294-308.
44. Combs HL, Shankland SJ, Setzer SV, Hudkins KL, Alpers CE. Expression of the cyclin kinase inhibitor, p27kip1, in developing and mature human kidney. Kidney Int 1998; 53:892-896.
45. Nagata M, Nakayama K, Terada Y, Hoshi S, Watanabe T. Cell cycle regulation and differentiation in the human podocyte lineage. Am J Pathol 1998; 153:1511-1520. Transitions occur in the expression of cyclins and CKIs at the capillary loop stage of development, at the same time that expression of 'mature' podocyte markers is seen.
46. Kitamura M, Fine LG. Evidence for TGF-β-mediated 'defense' of the glomerulus: a blackguard molecule rehabilitated. Exp Nephrol 1998; 6:1-6.
47. Shankland SJ, Floege J, Thomas SE, Nangaku M, Hugo C, Pippin J, et al. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int 1997; 52:404-413. In PHN, injury to podocytes leads to the upregulation of CKIs p21 and p27, limiting cell replication. This can be partly overcome by basis FGF, leading to increased mitosis and apoptosis.
48. Ophascharoensuk V, Fero ML, Hughes J, Roberts JM, Shankland SJ. The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury. Nat Mad 1998; 4:575-580.
49. Floege J, Kriz W, Schulze M, Susani M, Kerjaschki D, Mooney A. Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest 1995; 96:2809-2819.
50. Kihara K, Yatoita E, Kawasaki K, Yamamoto T. Limitations of podocyte adaption for glomerular injury in puromycin aminonucleoside nephrosis. Pathol Int 1995; 45:625-634.
51. Floege J, Hackmann B, Kliem V, Kriz W, Alpers CE, Johnson RJ, et al. Age-related glomerulosclerosis and interstital fibrosis in Milan normotensive rats: a podocyte disease. Kidney Int 1997; 51:230-243.
52. Gassler N, Elger M, Inoue D, Kriz W, Amling M. Oligonephronia, not exuberant apoptosis, accounts for the development of glomerulosclerosis in the bcl-2 knockout mouse. Nephrol Dial Transplant 1998; 13:2509-2518.
53. Shimojo H. Adaptation and distortion of podocytes in rat remnant kidney. Pathol Int 1998; 48:368-383. A thorough histopathological study demonstrating that FSGS develops along the podocyte damage-tuft adhesion-pathway in the classic subtotal nephrectomy model in the rat.
54. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99:342-348. The most profound study in humans so far to show evidence of podocyte loss with the progression of glomerular disease.
55. Hara M, Yanagihara T, Takada T, Itoh M, Matsuno M, Yamamoto T, et al. Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 1998; 18:35-41. In a variety of glomerular diseases but not non-glomerular renal diseases podocytes are lost into the urine (as indicated by specific markers in the urinary sediment); the amount in the urine increases in the acute phase of disease.
56. Hara M, Yanagihara T, Itoh M, Matsuno M, Kihara I. Immunohistochemical and urinary markers of podocyte injury. Pediatr Nephrol 1998; 12:43-48.
57. Rennke HG, Anderson S, Brenner BM. The progression of renal disease: Structural and functional correlations. In: Renal pathology. Tisher CC, Brenner BM (editors). Philadelphia: JB Lippincott Company; 1994. pp. 116-139.
58. Olson JL, Schwartz MM. The nephrotic syndrome: minimal change, focal segmental glomerulosclerosis, and miscellanous causes. In: Heptinstall's pathology of the kidney. Jenette JC, Olson JL, Schwartz MM, Silva FG (editors). Philadelphia: Lippincott-Raven; 1998. pp. 187-257.
59. Kriz W, Hosser H, Hähnel B, Gretz N, Provoost AP. From segmental glomerulosclerosis to total nephron degeneration and interstitial fibrosis: a histopathological study in rat models and human glomerulopathies. Nephrol Dial Transplant 1998; 13:2781-2798. A histopathological study presenting evidence that the linkage between glomerular and tubulointerstitial damage is underlain by misdirected filtration and filtrate spreading.
60. Chevalier J, Masurier C, Lavaud S, Michel O, Bariety J. Approach of cellular mechnisms of glomerulosclerosis in a model of accelerated aging the obese Zucker rat. CR Seances Soc Biol Fil 1995; 189:987-1007.
61. Kretzler M, Koeppen-Hagemann I, Kriz W. Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomized desoxycorticosterone rat. Virchows Arch A Pathol Anat Histol 1994; 425:181-193.
62. Shirato I, Hosser H, Kimura K, Sakai T, Tomino Y, Kriz W. The development of focal segmental glomerulosclerosis in Masugi nephritis is based on progressive podocyte damage. Virchows Arch 1996; 429:255-273.
63. Remuzzi A, Mazerska M, Gephardt GN, Novick AC, Brenner BM, Remuzzi G. Three-dimensional analysis of glomerular morphology in patients with subtotal nephrectomy. Kidney Int 1995; 48:155-162.
64. Iversen BM, Amann K, Kvam FI, Wang X, Ofstad J. Increased glomerular capillary pressure and size mediate glomerulosclerosis in SHR juxtamedullary cortex. Am J Physiol 1998; 274:F365-F373. This study clearly demonstrates that glomerular hypertrophy as well as increased glomerular capillary pressures may independently contribute to the manifestation of glomerulosclerosis.
65. Anderson S, Brenner BM. The role of nephron mass and of intraglomerular pressure in initiation and progression of experimental hypertensive-renal disorders. In: Hypertension: pathophysiology, diagnosis and management. Laragh JH, Brenner BM (editors). New York: Raven Press; 1995. pp. 1553-1568.
66. Smoyer WE, Mundel P, Gupta A, Welsh MJ. Podocyte-actinin induction precedes foot process effacement in experimental nephrotic syndrome. Am J Physiol 1997; 273:F150-F157.
67. Smoyer WE, Gupta A, Mundel P, Ballew JD, Welsh MJ. Altered expression of glomerular heat shock protein 27 in experimental nephrotic syndrome. J Clin Invest 1996; 97:2697-2704.
68. Smoyer WE, Mundel P. Regulation of podocyte structure during the development of nephrotic syndrome. J Mol Med 1998; 76:172-183. A review of changes in cytoskeletal components during the nephrotic syndrome.
69. Ebihara I, Kimura K, Nakamura T, Tomino Y, Yazaki Y, Nagai R, et al. Glomerular nonmuscle-type myosin heavy-chain isoform gene expression in glomerulosclerosis. Nephron 1998; 79:317-321.
70. Sasaki T, Jyo Y, Tanda N, Kawakami Y, Nohno T, Tamai H, et al. Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy. Kidney Int 1997; 51:301-309.
71. Kurihara H, Anderson JM, Farquhar MG. Increased Tyr phosphorylation of ZO-1 during modification of tight junctions between glomerular foot processes. Am J Physiol 1995; 286:F514-F524.
72. Shirato I, Sakai T, Kimura K, Tomino Y, Kriz W. Cytoskeletal changes in podocytes associated with foot process effacement in Masugi nephritis. Am J Pathol 1996; 148:1283-1296.
73. Inokuchi S, Shirato I, Kobayashi N, Koide H, Tomino Y, Sakai T. Re-evaluation of foot process effacement in acute puromycin aminonucleoside nephrosis. Kidney Int 1996; 50:1278-1287.
74. Verseput GH, Provoost AP, Braam BB, Weaning JJ, Koomans HA. Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat. J Am Soc Nephrol 1997; 8:249-259. A convincing study showing that the early onset of lowering glomerular capillary pressure protects fawn hypertensive hooded rats against the development of renal damage. Late onset cannot prevent further progression of the disease despite lowering glomerular capillary pressure.
75. Sharif K, Goyal M, Kershaw D, Kunkel R, Wiggins R. Podocyte phenotypes as defined by expression and distribution of GLEPP1 in the developing glomerulus and in nephrotic glomeruli from MCD, CNF, and FSGS. A dedifferentiation hypothesis for the nephrotic syndrome. Exp Nephrol 1998; 6:234-244.
76. Orikasa M, Matsui K, Oite T, Shimizu F. Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody. J Immunol 1988; 141:807-815.
77. Kawachi H, Kurihara H, Topham PS, Brown D, Shia MA, Orikasa M, et al. Slit diaphragm-reactive nephritogenic MAb 5-1-6 alters expression of ZO-1 in rat podocytes. Am J Physiol Renal Physiol 1997; 42:F984-F993.
78. Fujigaki Y, Nagase M, Hidaka S, Matsui K, Shirai M, Nosaka H, et al. Altered anionic GBM components in monoclonal antibody against slit diaphragm-injected proteinuric rats. Kidney Int 1998; 54:1491-1500.
79. Minto AW, Kalluri R, Togawa M, Bergijk EC, Killen PD, Salant DJ. Augmented expression of glomerular basement membrane specific type IV collagen isoforms (alpha3-alpha5) in experimental membraneous nephropathy. Proc Assoc Am Phys 1998; 110:207-217.
80. Singh AK, Mo W, Dunea G, Arruda JA. Effect of glycated proteins on the matrix of glomerular epithelial cells. J Am Soc Nephrol 1998; 9:802-810. Culturing glomerular epithelial cells on in-vitro glycated substrate leads to increased cell number, altered cadherin distribution and changes in extracellular matrix production.
81. Kemeny E, Mihatsch MJ, Durmuller U, Gudat F. Podocytes lose their adhesive phenotype in focal segmental glomerulosclerosis. Clin Nephrol 1995; 43:71-83.
82. Martin J, Steadman R, Knowlden J, Williams J, Davies M. Differential regulation of matrix metalloproteinases and their inhibitors in human glomerular epithelial cells in vitro. J Am Soc Nephrol 1998; 9:1629-1637.
83. Shirato I, Mundel P, Hug A, Ishidoj K, Kominami E, Tomino Y, Podocyte damage and the expression of cathepsin L (CL) in the absence of its intrinsic inhibitor in puromycin aminonucleoside (PAN) nephrosis [abstract]. J Am Soc Nephrol 1998; 9:509A.
84. Ding G, Van Goor H, Ricardo SD, Orlowski JM, Diamond JR. Oxidized LDL stimulate the expression of TGF-beta and fibronectin in human glomerular epithelial cells. Kidney Int 1997; 51:147-154.
85. Paizis K, Kirkland G, Polihronis M, Katerelos M, Kanellis J, Power DA. Heparin-binding epidermal growth factor-like growth factor in experimental models of membranous and minimal change nephropathy. Kidney Int 1998; 53:1162-1171.
86. McCarthy ET, Sharma M, Sharma R, Ge X-L. Focal segmental glomerulosclerosis (FSGS) factor increases albumin permeability (Pa1b) via product of cyclooxygenase pathway [abstract]. J Am Soc Nephrol 1998; 9:503A.
87. Hirose S, Yamamoto T, Feng L, Yaoita E, Kawasaki K, Goto S, et al. Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerutonephritis. J Am Soc Nephrol 1998; 9:408-416.
88. Mathis BJ, Kim SH, Calabrese K, Haas M, Seidman CE, Pollak MR. A locus for inherited focal segmental glomerulosclerosis maps to chromosome 19q13. Kidney Int 1998; 53:282-286.
89. Schumacher V, Scharer K, Wuhl E, Altrogge H, Bonzel KE, Guschmann M, et al. Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations. Kidney Int 1998; 53:1594-1600.
90. Burton C, Harris KPG. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996; 27:765-775.
91. Abbate M, Zoja C, Corna D, Capitanio M, Bertani T, Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 1998; 9:1213-1224. Early tubulointerstitial infiltrates cluster near the tubules with evident protein uptake. The authors suggest osteopontin as a possible mediator.
92. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-1456. A review of studies linking protein leakage to tubulointerstitial fibrosis.
93. Kriz W, Hosser H, Hähnel B, Provoost AP. Misdirected filtration from segmentally injured glomeruli contributes to progression of chronic renal disease [abstract]. J Am Soc Nephrol 1998; 9:614a.
94. Gandhi M, Olson JL, Meyer TW. Contribution of tubular injury to loss of remnant kidney function. Kidney Int 1998; 54:1157-1165.
95. Marcussen N. Biology of disease: atubular glomeruli and structural basis for chronic renal failure. Lab Invest 1992; 66:265-284.
96. van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, Sluiter WJ, de Zeeuw D, et al. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int 1997; 63 (Suppl.): S58-S62.
97. Ruggenenti P, Perna A, Benini R, Remuzzi G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol 1998; 9:2096-2101.
98. Bakris GL, Griffin KA, Picken MM, Bidani AK. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997; 15:1181-1185.
99. Linz W, Becker RHA, Schölkens BA, Wiemer G, Keil M, Langer KH. Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats. Kidney Int 1998; 54:2037-2044.
100. Weir MR, Dworkin LD. Antihypertensive drugs, dietary salt, and renal protection: how low should you go and with which therapy? Am J Kidney Dis 1998; 32:1-22.
101. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46:1182-1188.
102. Gloy J, Henger A, Fischer KG, Nitschke R, Bleich M, Mundel P, et al. Angiotensin II modulates cellular functions of podocytes. Kidney Int 1998; 67 (Suppl.):S168-S170.
103. Huber TB, Gloy J, Henger A, Schollmeyer P, Greger R, Mundel P, et al. Catecholamines modulate podocyte function. J Am Soc Nephrol 1998; 9:335-345. Again the title says it all.
104. Sharma M, Sharma R, Greene AS, McCarthy ET, Savin VJ. Documentation of angiotensin II receptors in glomerular epithelial cells. Am J Physiol 1998; 274:F623-F627. A second source (in addition to reference 101) demonstrating that podocytes are a target of angiotensin II.
105. Guasch A, Parham M, Zayas CF, Campbell O, Nzerue C, Macon E. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. J Am Soc Nephrol 1997; 8:793-798.
106. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54:889-896.
107. Macconi D, Ghilardi M, Abbate M, Morigi M, Bonassi M, Remuzzi G, et al. Lisinopril (LIS) prevents alteration in glomerular distribution of zonula occludens 1 (ZO-1) that develop in protreinuric MWF rats [abstract]. J Am Soc Nephrol 1998; 9:502A.
108. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54:1570-1580.
109. d'Agati V, Suh JI, Carbone L, Cheng JT, Appel G. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int 1989; 35:1358-1370.
110. Detwiler RK, Falk RJ, Hogan SL, Jennette JC. Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int 1994; 45:1416-1424.
111. Valeri A, Barisoni L, Appel GB, Seigle R, d'Agati V. Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study. Kidney Int 1996; 50:1734-1746.
112. d'Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998; 18:406-421. An in-depth review of all that is known about the renal involvement in HIV infection.
113. Barisoni L, Kriz W, Mundel P, d'Agati V. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10:51-61. Together with references 114 and 117 this is the most accurate study on collapsing FSGS. It presents strong evidence for a 'dysregulated' podocyte phenotype being responsible for glomerular obliteration.
114. Bariéty J, Nochy D, Mandet C, Jacquot C, Glotz D, Meyrier A. Podocytes undergo phenotypic changes and express macrophagic-associated markers in idiopathic collapsing glomerulopathy. Kidney Int 1998; 53:918-925. Together with references 113 and 117 this is the most accurate study on collapsing FSGS. It favors the dedifferentiation hypothesis.
115. Mundel P, Reiser J, Kriz W. Phenotypic conversion and differentiation of human and rat podocytes in vitro. J Am Soc Nephrol 1997; 8:697-705.
116. Orikasa M, Iwanaga T, Takahashi-Iwanaga H, Kozima K, Shimizu F. Macrophagic cells outgrowth from normal rat glomerular culture: possible metaplastic change from podocytes. Lab Invest 1996; 75:719-733.
117. Nagata M, Hattori M, Hamano Y, Ito K, Saitoh K, Watanabe T. Origin and phenotypic features of hyperplastic epithelial cells in collapsing glomerulopathy. Am J Kidney Dis 1998; 32:962-969. Together with references 113 and 114 this is the most accurate study on collapsing FSGS. It presents some evidence that the extracapillary cells on the glomerular tuft are derived from parietal epithelial cells.